|
| 36705597 | Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. | Clin Cancer Res | 2023 |
| 36513065 | Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. | Med | 2023 |
| 37279797 | A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma. | Oncologist | 2023 |
| 36647676 | Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial. | Clin Cancer Res | 2023 |
| 36705597 | Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. | Clin Cancer Res | 2023 |
| 37067240 | Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047. | Cancer Discov | 2023 |
| 37063293 | Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer. | Front Pharmacol | 2023 |
| 36470425 | Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth. | J Biol Chem | 2023 |
| 37046596 | Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer. | Cancers (Basel) | 2023 |
| 36991390 | First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. | J Exp Clin Cancer Res | 2023 |
| 37101182 | Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. | J Exp Clin Cancer Res | 2023 |
| 36991390 | First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. | J Exp Clin Cancer Res | 2023 |
| 37046596 | Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer. | Cancers (Basel) | 2023 |
| 37279797 | A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma. | Oncologist | 2023 |
| 37101182 | Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. | J Exp Clin Cancer Res | 2023 |
| 37067240 | Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047. | Cancer Discov | 2023 |
| 37063293 | Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer. | Front Pharmacol | 2023 |
| 36647676 | Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial. | Clin Cancer Res | 2023 |
| 36513065 | Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. | Med | 2023 |
| 36470425 | Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth. | J Biol Chem | 2023 |
| 36375380 | Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density. | Redox Biol | 2022 |
| 36375380 | Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density. | Redox Biol | 2022 |
| 35441778 | Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma. | Am J Med Genet A | 2022 |
| 35872332 | Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. | Pharmacol Ther | 2022 |
| 35929764 | Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP. | Pharmacol Res Perspect | 2022 |
| 36516994 | Photochemical Dimerization of Plakinidine B Leads to Potent Inhibition of the E3 Ubiquitin-Protein Ligase CBL-B. | Org Lett | 2022 |
| 36496977 | Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy. | Cells | 2022 |
| 35441778 | Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma. | Am J Med Genet A | 2022 |
| 36516994 | Photochemical Dimerization of Plakinidine B Leads to Potent Inhibition of the E3 Ubiquitin-Protein Ligase CBL-B. | Org Lett | 2022 |
| 36496977 | Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy. | Cells | 2022 |
| 35872332 | Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. | Pharmacol Ther | 2022 |
| 35929764 | Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP. | Pharmacol Res Perspect | 2022 |
| 34202500 | Agelasine Diterpenoids and Cbl-b Inhibitory Ageliferins from the Coralline Demosponge <i>Astrosclera willeyana</i>. | Mar Drugs | 2021 |
| 33747894 | Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. | Front Oncol | 2021 |
| 33882749 | In Vitro Ubiquitination Platform Identifies Methyl Ellipticiniums as Ubiquitin Ligase Inhibitors. | SLAS Discov | 2021 |
| 34202500 | Agelasine Diterpenoids and Cbl-b Inhibitory Ageliferins from the Coralline Demosponge <i>Astrosclera willeyana</i>. | Mar Drugs | 2021 |
| 34038132 | Sinularamides A-G, Terpenoid-Derived Spermidine and Spermine Conjugates with Casitas B-Lineage Lymphoma Proto-Oncogene B (Cbl-b) Inhibitory Activities from a <i>Sinularia</i> sp. Soft Coral. | J Nat Prod | 2021 |
| 33755810 | Rare Breast Cancer Subtypes. | Curr Oncol Rep | 2021 |
| 34479891 | Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab. | BMJ Case Rep | 2021 |
| 33882749 | In Vitro Ubiquitination Platform Identifies Methyl Ellipticiniums as Ubiquitin Ligase Inhibitors. | SLAS Discov | 2021 |
| 33755810 | Rare Breast Cancer Subtypes. | Curr Oncol Rep | 2021 |
| 33747894 | Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. | Front Oncol | 2021 |
| 34479891 | Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab. | BMJ Case Rep | 2021 |
| 34038132 | Sinularamides A-G, Terpenoid-Derived Spermidine and Spermine Conjugates with Casitas B-Lineage Lymphoma Proto-Oncogene B (Cbl-b) Inhibitory Activities from a <i>Sinularia</i> sp. Soft Coral. | J Nat Prod | 2021 |
| 32510664 | A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. | Oncologist | 2020 |
| 31999304 | Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia. | J Exp Med | 2020 |
| 32398324 | Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. | Clin Cancer Res | 2020 |
| 32270710 | Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. | Future Oncol | 2020 |
| 33126420 | Suberitamides A-C, Aryl Alkaloids from a <i>Pseudosuberites</i> sp. Marine Sponge that Inhibit Cbl-b Ubiquitin Ligase Activity. | Mar Drugs | 2020 |
| 32510664 | A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. | Oncologist | 2020 |